Matches in SemOpenAlex for { <https://semopenalex.org/work/W3164979025> ?p ?o ?g. }
- W3164979025 endingPage "771.e10" @default.
- W3164979025 startingPage "771.e1" @default.
- W3164979025 abstract "Patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) who relapse after allogeneic hematopoietic cell transplantation (allo-HCT) generally have poor overall survival (OS). Interventions that result in improved OS after relapse are not well established. The efficacy of second cellular therapy and specific indications are matters of debate. This study was conducted to evaluate factors associated with postrelapse survival and the efficacy of a second course of cellular therapy. We retrospectively analyzed consecutive patients with AML and MDS who underwent a first allo-HCT between 2010 and 2017 at our center but subsequently relapsed. One hundred and four patients with AML and 44 patients with MDS were included (total n = 148). Bone marrow (BM) and peripheral blood stem cell grafts were either unmodified or T cell-depleted (TCD) by CD34+ selection ex vivo. Forty-five patients (30.4%) received a second cellular therapy after relapse, either a second allo-HCT (n = 28; 18.9%) or donor leukocyte infusion (DLI) (n = 17; 11.5%). The median age at transplantation was 60 years (range, 24 to 78 years). The median time to relapse (TTR) after transplantation was 6.5 months (range, 1 to 60.9 months), and the ensuing median OS was 6 months (95% confidence interval [CI], 4.8 to 8.9 months). In univariable analysis, longer TTR, relapse type (measurable residual disease versus morphologic), relapse occurring in the most recent years, and receipt of cellular therapy after relapse were associated with better outcomes, whereas adverse cytogenetics and/or abnormality of TP53, as well as NPM1 mutation in patients with AML, were associated with adverse outcomes. Relapse type, year of relapse, and a variable resulting from the combination of TTR and receipt of second cellular therapy remained significantly associated with postrelapse survival in multivariable analysis. In a separate multivariable model, adjusted only for TTR, relapse type, and receipt of second cellular therapy, an adverse effect of NPM1 mutation on survival was confirmed. We could not show an effect of post-transplantation maintenance on survival after relapse. In both univariable and multivariable analysis, we found a positive association for second cellular therapy with survival after relapse in patients who relapsed early (<6 months) after allo-HCT and a similar trend in patients who relapsed late (>12 months) after transplantation. Two-year OS after a second cellular therapy was 44.9% (95% CI, 28.5% to 61.4%), and it was significantly better in patients with <5% BM blasts before cell infusion. We could not show different effects on survival after second cellular therapy for DLI versus second allo-HCT in univariable analysis. Survival after relapse is improving over time, but this remains a challenging event, especially for patients who relapse early after transplantation. We found that a second cellular therapy could offer a benefit even in these cases. Nonetheless, more research is needed to clarify the most appropriate treatment choices after relapse. These are probably driven by underlying genetic and immunologic conditions, which should be the focus of future studies." @default.
- W3164979025 created "2021-06-07" @default.
- W3164979025 creator A5000852934 @default.
- W3164979025 creator A5001124933 @default.
- W3164979025 creator A5002993817 @default.
- W3164979025 creator A5003194414 @default.
- W3164979025 creator A5006865761 @default.
- W3164979025 creator A5012678556 @default.
- W3164979025 creator A5016160764 @default.
- W3164979025 creator A5021595775 @default.
- W3164979025 creator A5023480510 @default.
- W3164979025 creator A5023530852 @default.
- W3164979025 creator A5027007983 @default.
- W3164979025 creator A5031349996 @default.
- W3164979025 creator A5036520753 @default.
- W3164979025 creator A5044340498 @default.
- W3164979025 creator A5044552886 @default.
- W3164979025 creator A5045167741 @default.
- W3164979025 creator A5047384277 @default.
- W3164979025 creator A5058746837 @default.
- W3164979025 creator A5059283771 @default.
- W3164979025 creator A5064076262 @default.
- W3164979025 creator A5066163702 @default.
- W3164979025 creator A5066934816 @default.
- W3164979025 creator A5069648775 @default.
- W3164979025 creator A5070096873 @default.
- W3164979025 creator A5078115930 @default.
- W3164979025 creator A5082333371 @default.
- W3164979025 creator A5085550690 @default.
- W3164979025 date "2021-09-01" @default.
- W3164979025 modified "2023-10-17" @default.
- W3164979025 title "Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy" @default.
- W3164979025 cites W1972061958 @default.
- W3164979025 cites W1995714834 @default.
- W3164979025 cites W2003289575 @default.
- W3164979025 cites W2004498221 @default.
- W3164979025 cites W2009379600 @default.
- W3164979025 cites W2017908149 @default.
- W3164979025 cites W2021412223 @default.
- W3164979025 cites W2036116596 @default.
- W3164979025 cites W2050519979 @default.
- W3164979025 cites W2064085613 @default.
- W3164979025 cites W2067620376 @default.
- W3164979025 cites W2074326274 @default.
- W3164979025 cites W2113946521 @default.
- W3164979025 cites W2116858301 @default.
- W3164979025 cites W2117206796 @default.
- W3164979025 cites W2150506134 @default.
- W3164979025 cites W2152197116 @default.
- W3164979025 cites W2270922886 @default.
- W3164979025 cites W2290664072 @default.
- W3164979025 cites W2326726820 @default.
- W3164979025 cites W2340869536 @default.
- W3164979025 cites W2341077074 @default.
- W3164979025 cites W2559537906 @default.
- W3164979025 cites W2567641264 @default.
- W3164979025 cites W2623089849 @default.
- W3164979025 cites W2770466614 @default.
- W3164979025 cites W2806682325 @default.
- W3164979025 cites W2880011386 @default.
- W3164979025 cites W2908841748 @default.
- W3164979025 cites W2910581135 @default.
- W3164979025 cites W2923556687 @default.
- W3164979025 cites W2924544666 @default.
- W3164979025 cites W2925256229 @default.
- W3164979025 cites W2948900598 @default.
- W3164979025 cites W2956554257 @default.
- W3164979025 cites W2983772550 @default.
- W3164979025 cites W3042846071 @default.
- W3164979025 cites W3101738346 @default.
- W3164979025 doi "https://doi.org/10.1016/j.jtct.2021.05.011" @default.
- W3164979025 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34033977" @default.
- W3164979025 hasPublicationYear "2021" @default.
- W3164979025 type Work @default.
- W3164979025 sameAs 3164979025 @default.
- W3164979025 citedByCount "12" @default.
- W3164979025 countsByYear W31649790252022 @default.
- W3164979025 countsByYear W31649790252023 @default.
- W3164979025 crossrefType "journal-article" @default.
- W3164979025 hasAuthorship W3164979025A5000852934 @default.
- W3164979025 hasAuthorship W3164979025A5001124933 @default.
- W3164979025 hasAuthorship W3164979025A5002993817 @default.
- W3164979025 hasAuthorship W3164979025A5003194414 @default.
- W3164979025 hasAuthorship W3164979025A5006865761 @default.
- W3164979025 hasAuthorship W3164979025A5012678556 @default.
- W3164979025 hasAuthorship W3164979025A5016160764 @default.
- W3164979025 hasAuthorship W3164979025A5021595775 @default.
- W3164979025 hasAuthorship W3164979025A5023480510 @default.
- W3164979025 hasAuthorship W3164979025A5023530852 @default.
- W3164979025 hasAuthorship W3164979025A5027007983 @default.
- W3164979025 hasAuthorship W3164979025A5031349996 @default.
- W3164979025 hasAuthorship W3164979025A5036520753 @default.
- W3164979025 hasAuthorship W3164979025A5044340498 @default.
- W3164979025 hasAuthorship W3164979025A5044552886 @default.
- W3164979025 hasAuthorship W3164979025A5045167741 @default.
- W3164979025 hasAuthorship W3164979025A5047384277 @default.
- W3164979025 hasAuthorship W3164979025A5058746837 @default.
- W3164979025 hasAuthorship W3164979025A5059283771 @default.